Second Targeted Therapeutic Approved for Use Based on Tumor Biomarker, Not Tumor Origin

Last week, the U.S. Food and Drug Administration (FDA) approved the second of a new wave of molecularly targeted therapeutics that can be used to treat patients with any type of cancer provided their tumor tests positive for a specific biomarker.

The therapeutic in question, entrectinib (Rozlytrek), was approved for treating adults and adolescents age 12 and older whose cancers have an NTRK gene fusion and who have no other effective treatment options.

Read More

AACR Cancer Progress Report 2018: Harnessing Research Discoveries for Patient Benefit

Today, the American Association for Cancer Research (AACR) released its eighth annual Cancer Progress Report. The report highlights how federally funded research that provides a deep understanding of the complexities of cancer is spurring advances across the clinical cancer care continuum and improving survival and quality of life for people around the world.

Read More

Advances in Tobacco Control

Cigarette smoking is the leading cause of death from lung cancer in the United States. That’s why November, Lung Cancer Awareness Month, is a good time to highlight new advances in tobacco control, such as the legislation that came into effect Nov. 1, 2017, in New Jersey that raises the minimum age of legal access to tobacco products to 21.

Read More

AACR Cancer Progress Report 2017: Harnessing Research Discoveries to Save Lives

Today, the American Association for Cancer Research (AACR) released its seventh annual Cancer Progress Report. The report highlights how federally funded research that provides a deep understanding of the biology of cancer is spurring advances across the clinical cancer care continuum that are improving survival and quality of life for people around the world.

Read More

AACR Cancer Progress Report 2016: Saving Lives Through Research

Today, the American Association for Cancer Research (AACR) released its sixth annual Cancer Progress Report. The report highlights how federally funded research powers progress against cancer and warns that accelerating …

Read More

Federally Funded Research Can Power Progress Against Cancer

Today, the American Association for Cancer Research (AACR) released the results of a national survey on American voter’s opinions about cancer and cancer research funding in conjunction with its fifth annual Cancer Progress Report. The report highlights how federally funded research can power progress against cancer and urges Congress and the administration to prioritize the growth of the budgets of the National Institutes of Health (NIH), National Cancer Institute (NCI), and U.S. Food and Drug Administration (FDA).

Read More

First FDA-approved Treatment for Rare Form of Non-Hodgkin Lymphoma

Last week, the U.S. Food and Drug Administration (FDA) announced the first-ever approval of a treatment for Waldenström macroglobulinemia, ibrutinib (Imbruvica).
Waldenström macroglobulinemia, which is also known as lymphoplasmacytic lymphoma, is …

Read More